Company / Financials
Aquestive Therapeutics, Inc. Financials
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$44.5M
FY2025 · -22.6% YoY
Net Income
-$83.8M
FY2025 · -89.8% YoY
Profit Margin
-188.1%
FY2025 · net income / revenue
ROE
-
FY2025 · return on equity
Total Assets
$160.4M
FY2025
Total Debt
$45.0M
-1.34x debt/equity
Equity
-$33.7M
FY2025
ROA
-52.2%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$44.5M-22.6% YoYNet Income HistoryProfit after all expenses and taxes-$83.8M-89.8% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$18.6M+3.8% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$71.1M-130.9% YoYSG&A Expense HistorySelling, general, and administrative expenses$79.8M+59.1% YoYR&D Expense HistoryResearch and development spending$17.2M-15.2% YoYInterest Expense HistoryCost of borrowing and debt obligations$6.3MIncome Tax HistoryTotal income tax expense$0+100.0% YoYEPS (Basic) HistoryBasic earnings per share-$0.51-292.3% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.51-292.3% YoY